Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baidu
BIDU
|
+$462M |
| 2 |
AGN
Allergan plc
AGN
|
+$390M |
| 3 |
AT&T
T
|
+$371M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$353M |
| 5 |
NextEra Energy
NEE
|
+$326M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.97B |
| 2 |
Meta Platforms (Facebook)
META
|
+$435M |
| 3 |
Pfizer
PFE
|
+$377M |
| 4 |
GE Aerospace
GE
|
+$354M |
| 5 |
Starbucks
SBUX
|
+$323M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.43% |
| 2 | Technology | 12.71% |
| 3 | Consumer Staples | 9.79% |
| 4 | Financials | 8.2% |
| 5 | Utilities | 8.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1901
SI-BONE Inc
SIBN
$813M
| $2.68M | ﹤0.01% |
224,500
+159,200
| +244% | +$2.92M |
|
|
BCLI
1902
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $2.68M | ﹤0.01% |
38,443
+16,181
| +73% | +$1.26M |
|
1903
DXP Enterprises
DXPE
$3.07B
| $2.67M | ﹤0.01% |
218,064
+61,664
| +39% | +$1.78M |
|
|
LUMO
1904
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $2.66M | ﹤0.01% |
313,091
-13,358
| -4% | -$187K |
|
1905
Avient
AVNT
$3.91B
| $2.65M | ﹤0.01% |
139,858
-695,400
| -83% | -$19.5M |
|
1906
Allstate
ALL
$69.6B
| $2.64M | ﹤0.01% |
28,800
-116,500
| -80% | -$12.7M |
|
1907
Kodiak Sciences
KOD
$2.84B
| $2.64M | ﹤0.01% |
55,359
-244,000
| -82% | -$14.6M |
|
|
ARC
1908
DELISTED
ARC Document Solutions, Inc.
ARC
| $2.63M | ﹤0.01% |
3,249,338
-302,300
| -9% | -$349K |
|
1909
Belden
BDC
$5.05B
| $2.63M | ﹤0.01% |
72,893
-220,300
| -75% | -$10.1M |
|
1910
Chemung Financial Corp
CHMG
$399M
| $2.63M | ﹤0.01% |
79,688
-5,700
| -7% | -$207K |
|
|
MSGN
1911
DELISTED
MSG Networks Inc.
MSGN
| $2.63M | ﹤0.01% |
257,600
-706,600
| -73% | -$10.1M |
|
1912
Nicolet Bankshares
NIC
$3.64B
| $2.62M | ﹤0.01% |
47,995
-12,400
| -21% | -$834K |
|
1913
Spero Therapeutics
SPRO
$73.5M
| $2.62M | ﹤0.01% |
324,303
-13,900
| -4% | -$123K |
|
1914
Acadia Realty Trust
AKR
$2.84B
| $2.61M | ﹤0.01% |
210,417
+63,016
| +43% | +$1.42M |
|
|
EMKR
1915
DELISTED
Emcore Corp
EMKR
| $2.6M | ﹤0.01% |
116,227
-6,230
| -5% | -$184K |
|
1916
Customers Bancorp
CUBI
$2.77B
| $2.6M | ﹤0.01% |
237,466
-48,943
| -17% | -$948K |
|
1917
Ferrari
RACE
$71.6B
| $2.59M | ﹤0.01% |
17,000
-261,568
| -94% | -$42.2M |
|
|
TCDA
1918
DELISTED
Tricida, Inc. Common Stock
TCDA
| $2.59M | ﹤0.01% |
117,800
+87,600
| +290% | +$2.81M |
|
1919
Standard Motor Products
SMP
$879M
| $2.59M | ﹤0.01% |
62,300
+22,100
| +55% | +$1.04M |
|
|
OIIM
1920
DELISTED
02Micro International
OIIM
| $2.59M | ﹤0.01% |
2,012,174
-74,486
| -4% | -$108K |
|
1921
Westamerica Bancorp
WABC
$1.38B
| $2.58M | ﹤0.01% |
43,900
+1,269
| +3% | +$78.9K |
|
1922
Option Care Health
OPCH
$3.54B
| $2.57M | ﹤0.01% |
271,756
-137,583
| -34% | -$2.02M |
|
1923
Townsquare Media
TSQ
$115M
| $2.57M | ﹤0.01% |
558,437
+82,000
| +17% | +$679K |
|
|
BDSI
1924
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $2.57M | ﹤0.01% |
678,400
-432,951
| -39% | -$2.13M |
|
1925
Acadia Pharmaceuticals
ACAD
$4.9B
| $2.57M | ﹤0.01% |
60,800
-670,200
| -92% | -$27.6M |
|
Similar funds
Renaissance Technologies's Q1 2020 Portfolio in Review
As of Q1 2020, Renaissance Technologies held 4,047 positions worth $103B, down 21% from $130B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Renaissance Technologies's Q1 2020 filing shows 573 new, 1,474 increased, 1,328 reduced and 645 closed positions. Its largest new stake was AT&T: 13,563,699 shares worth $299M. The largest sale was Tesla, an estimated $1.97B.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 21% a quarter earlier, followed by Technology and Consumer Staples.
- Renaissance Technologies's largest Q1 2020 buy was AT&T: 13,563,699 shares worth $299M.
- Renaissance Technologies added most to Baidu in Q1 2020, an estimated $462M increase.
- Renaissance Technologies's biggest Q1 2020 reduction was Tesla, cutting an estimated $1.97B.
- Renaissance Technologies fully exited Phillips 66 in Q1 2020, selling an estimated $214M.
- Renaissance Technologies's ten largest holdings make up 15% of its $103B portfolio in Q1 2020.
- Renaissance Technologies opened 573 new positions and closed 645 in Q1 2020.
- Renaissance Technologies's portfolio value fell 21% quarter-over-quarter to $103B.
Based on Renaissance Technologies's 13F filing for Q1 2020, filed 14 May 2020.